Additionally, we found that monocyte CD33 expression was higher in melanoma patients that responded to anti-PD-1 (Supplementary Figure 4B), and CD33 was also associated with better survival in melanoma patients within the TCGA dataset (Supplementary 4C). This evidence concerns the gene CD33 and melanoma.